8-K: Precision BioSciences Reports Q2 2026 Results, Clinical Milestones

Precision BioSciences announced second quarter 2026 financial results, highlighting key clinical advancements in its PBGENE-HBV and PBGENE-DMD programs, and a cash runway extending through 2028.

Summary

• Precision BioSciences reported its second quarter 2026 financial results, with a focus on clinical progress for its gene editing therapies.
• The company presented first clinical biopsy evidence of direct cccDNA elimination in its Phase 1 ELIMINATE-B trial for Hepatitis B, showing a 1-log reduction in cccDNA.
• PBGENE-HBV demonstrated sustained pgRNA loss in 100% of evaluable patients, a key biomarker for cccDNA elimination.
• Multiple clinical trial sites are actively recruiting for the Phase 1/2 FUNCTION-DMD trial for Duchenne muscular dystrophy.
• Next clinical updates for both PBGENE-HBV and PBGENE-DMD are anticipated by year-end 2026.
• The company ended the quarter with $112.4 million in cash, cash equivalents, and restricted cash, expected to fund operations through 2028.
• Net loss for the quarter was $32.7 million, or $(1.26) per share, an increase from the prior year's net loss of $23.5 million, or $(2.13) per share.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development, driven by significant clinical trial progress and a strong cash position, despite a widening net loss.

Positives

• First clinical biopsy evidence of direct cccDNA elimination in the ELIMINATE-B trial for Hepatitis B.
• PBGENE-HBV showed sustained pgRNA loss in 100% of evaluable patients, indicating durability of the elimination mechanism.
• Substantial S-antigen declines observed in 100% of treated patients in the ELIMINATE-B trial.
• No dose-limiting toxicities observed in the ELIMINATE-B trial; LNP-related hypotension issues have been identified and mitigated.
• Two clinical trial sites are active and recruiting for the FUNCTION-DMD trial for Duchenne muscular dystrophy.
• Cash balance of $112.4 million as of June 30, 2026, provides an expected cash runway through 2028.
• Addition to the Russell 2000 Index, enhancing market visibility with institutional investors.
• Promotions within the senior leadership team to support program advancement.

Negatives

• Net loss increased to $32.7 million for the quarter ended June 30, 2026, from $23.5 million in the prior year.
• Total other expense increased significantly to $13.5 million from $1.6 million, primarily due to non-cash fair value adjustments from warrant liability.
• Revenue was minimal ($18 thousand) for the quarter, down from less than $0.1 million in the prior year's quarter.

Risks

• The company's ability to become profitable.
• The ability to procure sufficient funding to advance its programs.
• Risks associated with capital requirements, anticipated cash runway, and requirements under debt instruments.
• The progression and success of its programs and product candidates.
• Limited ability or inability to assess the safety and efficacy of its product candidates.
• Competition in the genome editing, biopharmaceutical, and biotechnology fields.
• Potential product liability lawsuits and penalties.
• Delays or difficulties in patient enrollment for clinical trials.

Future Outlook

The company expects its current cash and cash equivalents, along with its at-the-market facility, to fund its cash runway through 2028, enabling it to achieve key data milestones for its PBGENE-HBV and PBGENE-DMD programs. Next clinical updates for both programs are targeted for year-end 2026, with initial safety data from the FUNCTION-DMD study also expected by year-end.

Management Comments

• "The second quarter marked a defining moment for Precision BioSciences and the hepatitis B field, with the first clinical biopsy evidence that a therapeutic agent can directly target and eliminate cccDNA data that validate both the science and the development strategy for PBGENE-HBV," said Michael Amoroso, Chief Executive Officer of Precision BioSciences.
• "We also continued to advance PBGENE-DMD, with patients now being recruited to participate in the FUNCTION-DMD study."
• "We entered 2026 with a clear plan to deliver multiple important clinical and operational milestones and we are executing against it with near-term data updates from both programs targeted for year end."

Industry Context

StockSavvy.ai notes that Precision BioSciences is operating in the highly competitive and innovative gene editing space, focusing on in vivo therapies for significant unmet medical needs like Hepatitis B and Duchenne Muscular Dystrophy. The reported clinical progress, particularly the cccDNA elimination data for Hepatitis B, represents a potentially significant advancement in the field, aiming for a curative approach rather than just suppression.

Management Changes

Stakeholder Impact

• Shareholders: Potential positive impact from promising clinical trial data and extended cash runway, but also negative impact from increased net loss and non-cash warrant liability adjustments.
• Employees: Potential positive impact from leadership promotions and continued company growth, but also risk associated with the long-term viability of a clinical-stage company.
• Creditors: The company's cash position and projected runway suggest a low immediate risk to creditors, but long-term success is tied to clinical and commercial outcomes.
• Partners (iECURE, TG Therapeutics, Imugene): Continued progress on partnered programs is beneficial for all parties involved.

Next Steps

• Continue enrolling patients in the Phase 1 ELIMINATE-B trial for PBGENE-HBV.
• Collect additional biopsies and blood biomarker data for PBGENE-HBV to inform Part 2 expansion dosing schedule.
• Provide additional updates on the ELIMINATE-B trial progress by the end of 2026.
• Continue advancing the Phase 1/2 FUNCTION-DMD trial for PBGENE-DMD.
• Provide initial safety data for the FUNCTION-DMD trial by the end of 2026.
• Continue development of partnered programs, including iECURE-OTC and azer-cel.

Key Dates

Recommendation

The company is making significant clinical progress, particularly with the PBGENE-HBV program showing promising early data for cccDNA elimination. The extended cash runway provides a solid foundation. However, the increased net loss and the significant non-cash loss from warrant liability adjustments warrant caution. The stock is likely to remain volatile, and a 'hold' position allows investors to await further clinical data and de-risk the pipeline before considering a more aggressive stance.

Keywords

gene editing, Hepatitis B, Duchenne muscular dystrophy, clinical trial, cccDNA elimination, ARCUS platform, PBGENE-HBV, PBGENE-DMD